GTCR Announces Sale of Antylia Scientific
- Editor
- May 28
- 2 min read
Whats Happening:
GTCR, a private equity firm, has completed the sale of Antylia Scientific to Brookfield Asset Management's private equity business and CDPQ for approximately $1.34 billion. This transaction marks the end of a decade-long partnership that saw significant growth and transformation of Antylia, a diversified life sciences company serving various industries including biopharmaceutical, clinical diagnostic, and environmental testing.
Key Moves:
GTCR sells Antylia Scientific for $1.34 billion to Brookfield Asset Management and CDPQ
Antylia completed 15 add-on acquisitions under GTCR's ownership
In 2021, Antylia divested its Masterflex bioprocessing business to Avantor Inc. for $2.9 billion
By The Numbers:
GTCR has invested more than $30 billion in over 280 companies since inception
GTCR currently manages more than $45 billion in equity capital
Antylia's Masterflex business was sold for $2.9 billion in 2021
Key Quotes:
"We are extraordinarily proud of the business transformation that Bernd, Jon and the entire Antylia team have been able to achieve over the last decade," said Sean Cunningham, Managing Director and Head of Healthcare at GTCR.
"The business has grown and evolved significantly in the decade we have partnered with them, and we look forward to watching the Antylia team's continued success as the business drives innovation in the life sciences industry," said Dean Mihas, GTCR Co-CEO and Managing Director.
"Antylia's continued growth and momentum would not have been possible without the thoughtful partnership from the entire GTCR team over the past decade," said Jonathan Salkin, CEO of Antylia.
Bottom Line:
The sale of Antylia Scientific represents a successful exit for GTCR after a decade of partnership and growth. This transaction showcases GTCR's ability to create value through its Leaders Strategy™, transforming Antylia into a diversified life sciences company through organic growth and strategic acquisitions. The deal also highlights the continued interest in life sciences tools businesses from major private equity players.
Comments